A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg

PHASE2CompletedINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

May 30, 2006

Primary Completion Date

June 13, 2008

Study Completion Date

March 13, 2019

Conditions
Advanced Breast CancerMetastatic Breast Cancer
Interventions
DRUG

Fulvestrant

intramuscular injection 250 mg \& 500 mg

Trial Locations (34)

1000

Research Site, Brussels

1062

Research Site, Budapest

2610

Research Site, Wilrijk

2800

Research Site, Tatabánya

3000

Research Site, Leuven

4032

Research Site, Debrecen

6720

Research Site, Szeged

8800

Research Site, Roeselare

9024

Research Site, Győr

19312

Research Site, Brivé

33000

Research Site, Bordeaux

40015

Research Site, Cluj-Napoca

63011

Research Site, Clermont-Ferrand

86000

Research Site, Poitiers

T6G 1Z2

Research Site, Edmonton

V5Z 4E6

Research Site, Vancouver

N1R 3G2

Research Site, Cambridge

N6A 4L6

Research Site, London

L1G 2B9

Research Site, Oshawa

P6A 2C4

Research Site, Sault Ste. Marie

M4C 3E7

Research Site, Toronto

M4N 3M5

Research Site, Toronto

H3T 1E2

Research Site, Montreal

G1S 4L8

Research Site, Québec

350 02

Research Site, Cheb

506 43

Research Site, Jičín

140 00

Research Site, Prague

85-796

Research Site, Bydgoszcz

80-214

Research Site, Gdansk

80-462

Research Site, Gdansk

31-115

Research Site, Krakow

10-228

Research Site, Olsztyn

Unknown

Research Site, Bucharest

Research Site, Istanbul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY